Abstract
A 32-year-old woman with highly active MS was infected with SARS-CoV-2 while on treatment with rituximab. She recovered and was symptom-free for 21 days before receiving rituximab and IVIg for comorbid hypogammaglobulinemia. Three days after the infusion she redeveloped respiratory symptoms and required admission. Three SARS-CoV-2 nasopharyngeal swabs and antibody testing was negative; however, bronchial alveolar lavage detected SARS-CoV-2. Reactivation of SARS-CoV-2 after rituximab for MS has not been reported but is a known risk in other conditions. The timing of anti-CD20 treatment after SARS-CoV-2 infection requires further investigation and individual consideration to reduce the risk of reactivation.
Keywords: COVID-19; Hypogammaglobulinemia; Multiple Sclerosis; Reinfection; Rituximab; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, multiple sclerosis, rituximab, Reinfection, Hypogammaglobulinemia, 【초록키워드】 Treatment, SARS-CoV-2, Antibody testing, multiple sclerosis, SARS-COV-2 infection, risk, IVIG, rituximab, Nasopharyngeal swab, Reactivation, nasopharyngeal swabs, respiratory, Admission, anti-CD20, Hypogammaglobulinemia, infusion, respiratory symptoms, other conditions, respiratory symptom, anti-CD20 treatment, Multiple, alveolar, reported, required, receiving, reduce, conditions, highly active, infected with SARS-CoV-2, 【제목키워드】 SARS-CoV-2, Multiple, sclerosis,